Loading
Predictmedix
Predictmedix AI Inc. develops multispectral-camera AI screening stations that detect infectious disease symptoms, drug or alcohol impairment, fatigue and vital signs. It also offers Mobilewellbeing, a remote patient monitoring and telehealth platform. It sells to workplaces, healthcare providers and defence sectors, including a 2025 alliance with Pacific Mechatronics for Asia-Pacific defence. It is publicly listed (CSE: PMED, OTC: PMEDF) and funds itself through equity raises, including a Post-IPO equity round in February 2025 and a private placement announced in October 2025. Trailing-12-month revenue was only about $3.5K as of October 2023 (PitchBook).
Funding
Every round, secondary, debt facility or acquisition involving Predictmedix that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
—